QVAR 80

Peak

beclomethasone dipropionate

NDAINHALATIONAEROSOL, METERED
Approved
Sep 2000
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10

Clinical Trials (5)

NCT02513160Phase 3Completed

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Started Sep 2015
713 enrolled
Persistent Asthma
NCT02040779Phase 3Completed

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Started Dec 2013
273 enrolled
Persistent Asthma
NCT02030457Phase 1Completed

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

Started Dec 2013
72 enrolled
Pharmacokinetics
NCT02040766Phase 3Completed

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

Started Dec 2013
628 enrolled
Asthma
NCT02031640Phase 3Completed

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Started Dec 2013
1,113 enrolled
Asthma

Loss of Exclusivity

LOE Date
May 18, 2031
63 months away
Patent Expiry
May 18, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
10022509
May 18, 2031
Product
10022510
May 18, 2031
Product
10086156
May 18, 2031
Product
9463289
May 18, 2031
Product
9808587
May 18, 2031
Product